Prednisone plus iguratimod versus prednisone plus leflunomide for IgG4‑RD with superficial organ involvement
Official title: Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Run by Peking Union Medical College Hospital · NCT05789030 · Data updated 2026-11-12
This 12‑month trial will test whether adding iguratimod or leflunomide to prednisone better prevents relapse in people with IgG4‑related disease affecting superficial organs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | April 30, 2026 |
| Study ends | April 30, 2026 |
| Registry record updated | April 7, 2026 |
| Trial ID | NCT05789030 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who meet the 2019 ACR/EULAR criteria for IgG4‑RD, have superficial organ involvement, require glucocorticoid treatment, and meet the trial's infection, malignancy, pregnancy, and medication restrictions are ideal candidates.
✕Probably not a fit
Patients with other autoimmune or malignant diseases, active infections (HIV, HBV, HCV, TB), pregnant or lactating women, those with severe irreversible organ damage, or prior biologic/immunosuppressant use are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This 12‑month open‑label randomized controlled trial will enroll 60 patients with IgG4‑related disease involving superficial organs and randomize them 1:1 to two treatment arms. One group receives prednisone tapered to ≤5 mg within three months plus iguratimod 25 mg twice daily, and the other receives the same prednisone taper plus leflunomide 10–20 mg once daily. Participants are followed with clinical evaluations, laboratory tests, imaging, and the IgG4‑RD Responder Index to monitor response and safety. The primary outcome is the difference in relapse rate at 12 months, with secondary outcomes including time to relapse, response rate, and side effects.
Why it matters
Potential benefit: If one combination reduces relapses with acceptable safety, patients could experience longer remission and reduced steroid exposure.
How similar studies have gone: While conventional immunosuppressants like leflunomide have some supportive case series and observational data in IgG4‑RD, randomized comparisons between iguratimod and leflunomide for this condition are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Fulfillment of the 2019 American College of Rheumatology/European League against Rheumatology (ACR/EULAR) IgG4-related disease classification criteria; 2. Newly-onset or relapsed patients who requires initiation or continuation of glucocorticoids treatment; 3. The addition of glucocorticoids was started at lower than 10 mg/d. Exclusion Criteria: * 1\. Patients who were diagnosed as other autoimmune diseases; 2. Patients who were diagnosed as malignant diseases; 3. Pregnant and lactating women； 4. Active infection: HIV, HCV, HBV, TB； 5. Severe irreversible damage of organ function; 6. Receipt of any biologic therapy or immunosuppressive agent other than GCs.
Where it's running
-
Peking Union Medical College Hospital
Beijing, China Recruiting
Study contacts
- Principal investigator: Wen Zhang, MD — Peking Union Medical College Hospital
- Study coordinator: Yunyun Fei, MD
- Email: feiyunyun@pumch.cn
- Phone: 01069159953
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.